JP2005522228A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522228A5
JP2005522228A5 JP2003584732A JP2003584732A JP2005522228A5 JP 2005522228 A5 JP2005522228 A5 JP 2005522228A5 JP 2003584732 A JP2003584732 A JP 2003584732A JP 2003584732 A JP2003584732 A JP 2003584732A JP 2005522228 A5 JP2005522228 A5 JP 2005522228A5
Authority
JP
Japan
Prior art keywords
polypeptide
expression
nkcc1
nucleic acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003584732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522228A (ja
Filing date
Publication date
Priority claimed from GB0208332A external-priority patent/GB0208332D0/en
Priority claimed from GB0229875A external-priority patent/GB0229875D0/en
Application filed filed Critical
Priority claimed from PCT/GB2003/001589 external-priority patent/WO2003087840A2/en
Publication of JP2005522228A publication Critical patent/JP2005522228A/ja
Publication of JP2005522228A5 publication Critical patent/JP2005522228A5/ja
Pending legal-status Critical Current

Links

JP2003584732A 2002-04-11 2003-04-11 癌に関与するタンパク質 Pending JP2005522228A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0208332A GB0208332D0 (en) 2002-04-11 2002-04-11 Protien
GB0229875A GB0229875D0 (en) 2002-12-21 2002-12-21 Protein involved in cancer
PCT/GB2003/001589 WO2003087840A2 (en) 2002-04-11 2003-04-11 Protein involved in cancer

Publications (2)

Publication Number Publication Date
JP2005522228A JP2005522228A (ja) 2005-07-28
JP2005522228A5 true JP2005522228A5 (enExample) 2006-07-06

Family

ID=29252444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003584732A Pending JP2005522228A (ja) 2002-04-11 2003-04-11 癌に関与するタンパク質

Country Status (5)

Country Link
US (1) US20060088537A1 (enExample)
EP (1) EP1497658A2 (enExample)
JP (1) JP2005522228A (enExample)
AU (1) AU2003227861A1 (enExample)
WO (1) WO2003087840A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0422211D0 (en) * 2004-10-06 2004-11-03 Randox Lab Ltd Method
DE102004052707A1 (de) * 2004-10-22 2006-04-27 Beiersdorf Ag Schweiß verringernde kosmetische Zubereitung
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
US20090069189A1 (en) * 2007-09-11 2009-03-12 Cancer Prevention And Cure, Ltd. Method of identifying proteins in human serum indicative of pathologies of human lung tissues
EP2396024A4 (en) * 2009-02-11 2013-02-27 Lantmaennen As Faktor Ab USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION
EP3444359A1 (en) 2009-03-12 2019-02-20 Cancer Prevention And Cure, Ltd. Methods of identification of non-small cell lung cancer
WO2018187496A2 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
US20200033347A1 (en) * 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009369A (es) * 1999-03-15 2003-06-06 Eos Biotechnology Inc Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal.
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20030068636A1 (en) * 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
KR101008758B1 (ko) * 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP

Similar Documents

Publication Publication Date Title
JP2021167805A (ja) SARS−CoV−2感染症を診断するための方法および試薬
JP2025133108A5 (enExample)
RU2013113439A (ru) Идентификация опухолеассоциированных антигенов для диагностики и терапии
JP2005504513A5 (enExample)
JP2015533788A5 (enExample)
JP2008517928A5 (enExample)
JP2009544284A5 (enExample)
DE69737788D1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
JP2018518151A5 (enExample)
JP2014503180A5 (enExample)
JP2005522228A5 (enExample)
KR20120057562A (ko) 피브린 및 피브리노겐 분해 생성물의 검출 및 관련된 제조 방법 및 암의 검출 및 모니터링을 위한 용도
JP2007523644A5 (enExample)
JP2004513614A5 (enExample)
JP2003527109A5 (enExample)
JP2007527995A (ja) 分子上のエピトープの免疫検出のための試薬、キット及び方法
JP2007513873A5 (enExample)
JP5821198B2 (ja) 抗il28b抗体及びこれを用いたil28bの測定方法
JP2008500833A5 (enExample)
JP7044721B2 (ja) Hcvコア抗原の迅速な検出のための前処理法
CN109313201B (zh) 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体
WO2014096386A1 (en) Anti-hdac11 antibodies
JP2005522229A5 (enExample)
JP2004515215A5 (enExample)
JP2008535855A5 (enExample)